{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:12Z","timestamp":1792269492605,"version":"4.4.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a B-cell\u2013mediated autoimmune disease associated with aquaporin-4 (AQP4-IgG) antibodies in which patients may require anticoagulation, including heparin for venous thromboembolism prophylaxis, thereby exposing them to a risk of heparin-induced thrombocytopenia (HIT), an immune-mediated complication caused by antibodies directed against PF4\u2013heparin complexes. Whether anti-AQP4\u2013mediated autoimmunity contributes to susceptibility to anti-PF4\/heparin immune responses warrants further investigation. Four cases of suspected or confirmed HIT in patients with NMOSD are presented, together with a review of the current literature. In our NMOSD cohort (n=90), 24 patients underwent therapeutic plasma exchange (TPE), among whom HIT was suspected in four cases (16,7% suspected and 8.3% immunoassay positive). These findings underscore the need for vigilance regarding HIT and thromboembolic complications in NMOSD patients undergoing relapse treatment with TPE. Strategies for the safe continuation of TPE using non-heparin anticoagulation and considerations for outpatient management are also addressed. Awareness of this potential association may facilitate earlier recognition and appropriate management in clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1884839","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:30Z","timestamp":1789364370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Confirmed and suspected heparin-induced thrombocytopenia during therapeutic plasma exchange in neuromyelitis optica spectrum disorder: a single-centre case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Aleksandra","family":"Podlecka-Pi\u0119towska","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Rychter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sujkowska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Zakrzewska-Pniewska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Nojszewska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001168","article-title":"Neuromyelitis optica spectrum disorders","volume":"28","author":"Costello","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","article-title":"IPND 2025: Revised consensus criteria, classification, and nomenclature for neuromyelitis optica spectrum disorders","author":"Wingerchuk","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: Heparin. A statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-induced thrombocytopenia a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.08.004","article-title":"Heparin-induced thrombocytopenia in patients receiving plasma exchange","volume":"127","author":"Limaye","year":"2014","journal-title":"Am J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.13259","article-title":"Clinical analysis of heparin-induced thrombocytopenia due to therapeutic plasmapheresis with heparin anticoagulation","volume":"38","author":"Lv","year":"2025","journal-title":"Semin Dial"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12316","article-title":"Heparin-induced thrombocytopenia following plasma exchange in patients with demyelinating neurological disease","volume":"37","author":"Arachchillage","year":"2015","journal-title":"Int J Labor Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.11.012","article-title":"Anti-PF4 antibodies and their relationship with COVID infection","volume":"46","author":"Yang","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000066","article-title":"Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia","volume":"21","author":"McKenzie","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med (United Kingdom)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12308-025-00665-3","article-title":"Age, gender, and ethnicity are associated with higher all-cause mortality in hospitalized patients with heparin-induced thrombocytopenia: a nationwide analysis","volume":"18","author":"Devlin","year":"2025","journal-title":"J Hematopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1208977","article-title":"Case report: Granzyme-B expression by T- and B- cells during severe AQP4-positive neuromyelitis optica spectrum disorder with fatal venous thromboembolism outcome","volume":"14","author":"Boldrini","year":"2023","journal-title":"Front Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4T\u2019s score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemostasis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000719","article-title":"Management of autoimmune hemolytic anemia","volume":"2025","author":"Barcellini","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251322549","article-title":"Systematic literature review of DOACs as treatment for confirmed or suspected heparin-induced thrombocytopenia (HIT)","volume":"59","author":"Steinmetz","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21222","article-title":"Anticoagulation techniques in apheresis: from heparin to citrate and beyond","volume":"27","author":"Lee","year":"2012","journal-title":"J Clin Apher"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16018","article-title":"Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: A systematic review","volume":"60","author":"Onuoha","year":"2020","journal-title":"Transfusion"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:31Z","timestamp":1789364371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1884839"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1884839","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1884839"}}